This warrants the need for close monitoring and care during treatment. Providers often avoid prescribing sildenafil to patients with certain health conditions, which hinders the market growth.
According to data provided by Cleveland Clinic Foundation, a non-profit academic medical center, around 30-41% of men suffer from ED by the age of 40. The increasing geriatric population and age-related health issues are contributing to the growing patient pool. The high unmet needs of ED patients are expected to drive the demand for sildenafil drugs in the near future. With improving awareness and acceptance for ED treatment, the adoption of sildenafil is likely to increase among patients. Expiry of patents leading to launch of generics: The patent expiry of branded sildenafil drugs such as Viagra has led to the launch of generic versions by many pharmaceutical companies.
The low cost of generics compared to branded equivalents is boosting their adoption. Companies are focused on developing generic sildenafil formulations to capture the market share. The availability of generics has made ED treatment more accessible and affordable, thereby driving the growth of the sildenafil drug market. Favorable reimbursement policies and government support: The reimbursement coverage for ED drugs by public and private healthcare insurance providers is improving in many countries. This is encouraging patients to opt for sildenafil treatment.
Initiatives by governments and NGOs to spread awareness about ED and available treatment options led to the greater adoption of sildenafil drugs. Government support to expand healthcare infrastructure is also fueling the growth of the sildenafil drug market. Emerging use in other therapeutic applications: While ED remains the primary application sildenafil has shown promise in other indications like pulmonary hypertension and altitude sickness. The widening scope of sildenafil in other untapped applications and ongoing research for further therapeutic uses represents significant growth opportunities for the market in the long run. Expanding clinical evidence and physician prescriptions will support the increasing utilization of sildenafil drugs. Social stigma surrounding ED: The social stigma and embarrassment associated with sexual disorders like erectile dysfunction often prevents patients from seeking medical assistance.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Viagra Generic | 100mg | 90 + 6 Pills | 129.02€ 122.88€ | |
| Viagra Generic | 25mg | 10 Pills | 25.19€ 23.99€ | |
| Kamagra | 100mg | 180 + 6 Pills | 436.79€ 415.99€ | |
| Kamagra Polo | 100mg | 20 Pills | 83.56€ 79.58€ | |
| Viagra Generic | 50mg | 360 + 10 Pills | 225.33€ 214.60€ | |
| Viagra Generic | 25mg | 30 + 4 Pills | 47.97€ 45.69€ | |
| Viagra Generic | 150mg | 30 + 2 Pills | 72.32€ 68.88€ | |
| Kamagra | 100mg | 84 + 6 Pills | 264.44€ 251.85€ | |
| Kamagra Polo | 100mg | 32 Pills | 125.88€ 119.89€ | |
| Kamagra Oral Jelly | 100mg | 30 + 5 Sachets | 136.20€ 129.71€ | |
| Viagra Generic | 200mg | 90 + 6 Pills | 170.79€ 162.66€ | |
| Viagra Generic | 100mg | 30 + 4 Pills | 60.91€ 58.01€ | |
| Viagra Generic | 150mg | 360 + 10 Pills | 423.48€ 403.31€ | |
| Viagra Generic | 100mg | 270 + 10 Pills | 270.47€ 257.59€ |
Many patients are hesitant to discuss sexual problems with doctors.
Development of novel drug delivery systems: Pharmaceutical companies are engaged in developing innovative drug delivery systems such as oral disintegrating tablets, nasal sprays, topical gels, and others to improve efficacy, safety, convenience, and compliance of sildenafil treatment. The advent of advanced drug delivery platforms provides an opportunity to differentiate brand offerings and gain competitive advantage in the market. Biomaterials, nanotechnology, 3D printing is being leveraged sildenafil oral solution to develop novel sildenafil formulations. Growing OTC market: The approval of sildenafil as an over-the-counter (OTC) drug in major markets such as the U.S., U.K., European Union (U.N), and others has opened up new expansion possibilities. The OTC status eliminates the need for a doctor’s prescription and improves accessibility for patients.
Companies are introducing branded and generic OTC sildenafil products to tap into this high-growth consumer segment. The increasing demand from pharmacy chains and retail outlets will accelerate OTC sales. Rising demand in emerging economies: Developing countries in Asia Pacific, Latin America, and Middle East & Africa represent untapped markets for sildenafil drugs. The improving healthcare expenditures, increasing health literacy, growing middle-class population, and rising cases of ED offer significant opportunities for market players. Companies are establishing operations in these countries to leverage the high-growth potential.
Local partnerships, marketing initiatives, and competitive pricing are key strategies. Combination therapies and pipeline products: The development of fixed-dose combination drugs of sildenafil with other active ingredients could boost therapeutic efficacy, thereby reduce side effects and improve patient compliance. Pipeline sildenafil drugs with novel mechanisms of action also offer scope for product differentiation and penetration of untapped patient pools. The launch of innovative pipeline products and combination drugs will help widen the application range of sildenafil. Uncover macros and micros vetted on 75+ parameters: Get instant access to report Increasing adoption of ePharmacies: The growth of online pharmacy platforms and ecommerce is driving the purchase of sildenafil drugs via ePharmacies. The stigma limits the number of patients who undergo diagnosis and receive appropriate sildenafil treatment. Efforts to spread awareness and sensitize the population regarding ED will help counter this restraint.
These digital platforms offer convenience, discounted prices, doorstep delivery, and easier access. They also provide privacy to patients in buying sensitive medications like sildenafil. Market players are strengthening their digital presence through partnerships with ePharmacy retailers. Social media marketing on digital channels will continue fueling ePharmacy sales. Strategic collaborations and partnerships: The sildenafil drug market has been witnessing increasing partnerships, collaborations activities between pharmaceutical companies.
Strategic deals enable companies to mutually leverage their capabilities, expand product portfolios, enter new markets, and gain economies of scale. Moreover, collaborations between pharma firms and academic institutes provide access to research advancements. The trend of strategic deals is sildenafil 50mg tablet expected to rise, thereby driving innovation and growth of the sildenafil drug market. Preference for value-added generics: Majority sildenafil drugs going off-patent has intensified competition from generics. However, companies are focusing on value-added generic formulations to gain advantage.
These involve aspects like advanced delivery systems, faster dissolution, extended release, higher bioavailability, better stability, and so on. Patients and providers are likely to prefer such value-added generics that offer added benefits. This will compel companies to invest in developing differentiated generic sildenafil products. Direct-to-consumer (DTC) advertising: Pharmaceutical companies are adopting aggressive marketing strategies like direct-to-consumer advertising to boost awareness and adoption of their sildenafil offerings. DTC advertising through television, print, radio, social media helps inform patients about available branded treatment options. Availability of alternatives and counterfeits: Patients have access to alternative non-medical remedies for ED like supplements, devices, acupuncture, and others. Though less effective, these can restrict the drug treatment patient pool. The easy availability of counterfeit versions also poses a major challenge. Counterfeits contain harmful substances and can have serious health impacts. Ensuring access to safe, regulated sildenafil drugs remains a challenge in developing regions.
Authorities are implementing stringent anti-counterfeiting measures to curb this.
Companies also engage in disease awareness campaigns to improve education about ED. The growing DTC marketing efforts are expected to increase patient flow for sildenafil drugs. Adverse effects and safety concerns: Sildenafil usage has been associated with some side effects like headaches, flushing, visual disturbances, back pain and gastrointestinal issues. There have also been isolated incidents of serious effects like hearing loss and vision loss. Safety concerns regarding adverse effects thus limit the full adoption of sildenafil drugs. Counterbalances: The key market players should increase on adopting strategies to reduce the side effects of the sildenafil drugs that often results in hearing and vision loss. Strict anti-counterfeiting measures needs to be implemented to curb the problems faced due to counterfeit drugs. Global sildenafil 45 mg chewable tablets Sildenafil Drug Market Share (%), By Dosage Form, 2026 To learn more about this report, Request Free Sample In August 16, 2023, Mangoceuticals, Inc., a healthcare company, launched its second Mango ED product, which combines the active ingredient in Viagra, sildenafil, with the company's original compound. Interested customers can choose between the company's original Tadalafil-based Mango ED solution and a sildenafil-based Mango ED product through its telemedicine platform. In June 22, 2023, CMP Pharma, a pharmaceutical company, launched Liqrev, the first U.S. FDA-approved ready-made oral liquid of sildenafil.
| Dosage (mg) | Average Price per Tablet (€) | Common Brands |
|---|---|---|
| 25 | 8 | Generic, Kamagra |
| 50 | 12 | Pfizer, Bluepill |
| 100 | 15 | Viagra, Revatio |
The drug is intended to treat pulmonary arterial hypertension in people who are unable of swallowing tablets. In October 2022, Zydus Group, a pharmaceutical company, announced that it has received final approval from the U.S.
| Legislation / Regulation | Effect on Prices | Remarks |
|---|---|---|
| Price Capping Policies | Stabilized prices | Limits maximum markup |
| Import Regulations | Slight increase | Adds compliance costs |
| Patent Laws | Maintains higher prices | Longer patent protection for brand-name drugs |
Food and Drug Administration (FDA) to market sildenafil for oral suspension USP 10 mg/ml. Sildenafil for oral suspension is used to treat pulmonary hypertension. In September 2019, Lupin, a pharmaceutical company, launched sildenafil tablets USP, 25 mg, 50 mg, and 100 mg, having received an approval from the U.S. Food and Drug Administration.
| Brand | Price per Tablet (€) | Pack Size | Manufacturer |
|---|---|---|---|
| Viagra | 15 | 30 | Pfizer |
| Sildenafil UK | 10 | 20 | Generic Labs |
| Kamagra | 8 | 10 | Ajanta Pharma |
| Revatio | 18 | 30 | Pfizer |
In October 2022, Pfizer Inc., a pharmaceutical company, Roman, an digital healthcare clinic for men, announced a supply agreement to offer Roman members access to the only U.S. FDA approved authorized generic version of Viagra (sildenafil citrate).
Sildenafil API and finished dose manufacturers (e.g., Pfizer/Viatris, Teva, Cipla, Aurobindo) Urologists and cardiologists prescribing sildenafil for ED and PAH CMI Data Analytics Tool, Proprietary CMI Existing Repository of information for last 10 years. Definition: The sildenafil drug market refers to the pharmaceutical drugs and formulations containing sildenafil citrate as the active ingredient indicated for the treatment of erectile dysfunction (ED) and pulmonary arterial hypertension (PAH).